Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2023: revenue JPY 4,027 billion, from the 20-F
Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2023 it reported revenue of JPY 4,027 billion ($29.8 billion at the year's average rate), up 12.8% on the year before. Its profit attributable to shareholders was JPY 317 billion, up 37.8%, and diluted earnings per share JPY 201.94.
this yearthe year beforeIn yen as filed. Hover a bar for its figure.
Income statement (profit and loss)
| Year to | Mar 2022 | Mar 2023 |
|---|---|---|
| Revenue | 3,569 | 4,027 |
| Cost of sales | 1,107 | 1,244 |
| Research and development | 526 | 633 |
| Operating profit | 461 | 491 |
| Finance costs | 167 | 170 |
| Profit before tax | 303 | 375 |
| Income tax | 72.4 | 58.1 |
| Profit for the year | 230 | 317 |
| Profit attributable to shareholders | 230 | 317 |
| Filing | 20-F | 20-F |
Read more
A line the company does not file under the standard tag is left out rather than estimated.JPY per ordinary share, as filed.
Cash flow
| Year to | Mar 2022 | Mar 2023 |
|---|---|---|
| Cash from operations | 1,123 | 977 |
| Purchase of property, plant and equipment | 123 | 141 |
| Free cash flow | 1,000 | 836 |
| Cash from investing | -198 | -607 |
| Cash from financing | -1,070 | -709 |
| Depreciation and amortisation | 583 | 664 |
| Buybacks | 77.5 | 26.9 |
| Dividends paid | 284 | 279 |
| Filing | 20-F | 20-F |
JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet
| Year to | Mar 2022 | Mar 2023 |
|---|---|---|
| Funded by | ||
| Equity attributable to shareholders | 5,683 | 6,354 |
| Non-controlling interests | 0.5 | 0.5 |
| Borrowings, as filed | 4,345 | 4,382 |
| Lease liabilities | 465 | 479 |
| Other liabilities | 2,684 | 2,741 |
| Total equity and liabilities | 13,178 | 13,958 |
| Owned | ||
| Property, plant and equipment | 1,583 | 1,691 |
| Goodwill | 4,408 | 4,791 |
| Other intangible assets | 3,819 | 4,270 |
| Cash and cash equivalents | 850 | 534 |
| Trade and other receivables | 697 | 649 |
| Inventories | 853 | 986 |
| Other assets | 969 | 1,037 |
| Total assets | 13,178 | 13,958 |
| Filing | 20-F | 20-F |
JPY billion, at each fiscal year end.
Ratios on the filed lines
| Year to | Mar 2022 | Mar 2023 |
|---|---|---|
| Operating margin | 12.9% | 12.2% |
| Net margin | 6.4% | 7.9% |
| Free cash flow margin | 28.0% | 20.8% |
| Return on year-end equity | 4.0% | 5.0% |
| Effective tax rate | 23.9% | 15.5% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
The exchange rates used
| Year to | Average over the year JPY per US dollar | At the year end JPY per US dollar |
|---|---|---|
| Mar 2017 | 108.00 | 111.41 |
| Mar 2018 | 110.75 | 106.20 |
| Mar 2019 | 110.86 | 110.68 |
| Mar 2020 | 108.70 | 107.53 |
| Mar 2021 | 106.06 | 110.61 |
| Mar 2022 | 112.24 | 121.44 |
| Mar 2023 | 135.17 | 132.75 |
| Mar 2024 | 144.31 | 151.22 |
| Mar 2025 | 152.25 | 149.90 |
| Mar 2026 | 150.48 | 159.08 |
Read more
Profit and loss, cash flow and EPS use the average of the daily rates over each fiscal year; the balance sheet uses the rate on the year end, or the last one before it. Ratios are the same in either currency. The filed figures are the ones in yen.20-F for the year to 31 March 2023, filed 25 June 2025: the filing. The figures are in yen as filed.